Source Fact: Hana Securities / Published on June 29, 2026
Investment Opinion & Target Price: BUY (Maintain) / 510,000 KRW
Key Momentum: Blasting quarter-over-quarter (QoQ) revenue growth in the European region (UK, Spain, Germany, etc.) and global footprint expansion, coupled with offline channel penetration in the US and Amazon Prime Day effects
📊 1. [Section Title: Valuation Indicators and Investment Metrics Analysis]
- Target Price & Investment Rating: Maintaining a BUY rating and a 12-month target price of 510,000 KRW for APR (278470). Applying a valuation premium is deemed appropriate given the successful early entry into the global market.
- Annual Earnings Forecast (2026F): Annual revenue for 2026 is projected to grow by 84% year-over-year to approximately 2.8 trillion KRW (2,586.4 billion KRW on the financial statement), with operating profit estimated at 631.1 billion KRW. This represents an explosive top-line growth despite the high base burden from the previous year.
- Valuation & Profitability Metrics: The estimated Return on Equity (ROE) for 2026 stands at an extremely high level of 73.25%, maintaining immense profitability, while the Price-to-Earnings (PER) ratio is 28.15x and the Price-to-Book (PBR) ratio is 15.58x. The current stock price trades at a 12MF PER of 21.6x, representing an attractive valuation range given the robust 2025–2028 CAGR EPS growth of 45%.
- Financial Cost Burdens: While cost expansion elements exist—such as rising freight expenses including European air transport, Prime Day marketing expenses, and increased TikTok Shop ‘deals for your days’ (DFYD) promotion commissions—they are thoroughly offset by the massive operating leverage effect driven by top-line revenue growth.
🚀 2. [Section Title: Total Addressable Market (TAM) & Detailed Earnings Forecasts]
- 2Q26 Quarterly Earnings Preview: Second-quarter consolidated revenue is projected to grow 112% YoY to 695.1 billion KRW, and operating profit is expected to surge 109% YoY to 176.6 billion KRW, maintaining a solid operating profit margin of over 25%.
- Global Market TAM Expansion & Achievements:
- US Market: Driven by the expansion of brick-and-mortar stores like Target and Walmart alongside Amazon Prime Day event effects, US revenue is forecast to hit 303.0 billion KRW (YoY +215%). During Prime Day, the company achieved the feat of placing 10 products within the Beauty Top 100.
- European Market: Beginning with the UK in 1Q, regional operations officially rolled out into Spain, Germany, France, and Italy in 2Q, pushing estimated European revenue up by over 50% QoQ to 60.0 billion KRW.
- Upcoming Frontiers: Following the US and Europe, regional footprints are scheduled to expand sequentially into China and Central/South America, with momentum expected to accelerate via Silicon2’s Mexico subsidiary operations.
- Core Product Lineup Momentum: Supply shortages for the ‘Zero Pore Pad’ have eased, unlocking additional revenue potential, while the ‘Collagen Jelly Cream’ and ‘PDRN Ampoule’ have successfully anchored themselves as steady sellers. New product rollouts (PDRN Multi-Balm, Vitamin C Capsule Cream, PDRN Eye Serum, etc.) are continuously scaling up their revenue contributions.
- New Business Operational Pipeline: The ‘Booster Pro X2’ was launched in the US at the end of June to initiate aggressive second-half marketing. The new medical device business (EBD/Skin Booster) is currently undergoing licensing processes, with a dedicated 10-person sales organization already established to initiate immediate operations upon regulatory approval.
📝 Editor’s Comment (by K-STOCK Editor)
APR’s global expansion playbook offers a textbook example of a ‘fast follower’ strategy that highly efficiently leverages Korea’s cosmetic infrastructure—specifically ODM and distribution network partnerships. Generating this level of staggering top-line growth (2026E YoY +84%) within the indie brand space while simultaneously capturing an operating profit margin north of 25% stems directly from their rapid global execution. Although short-term cost outlays such as escalating marketing expenditures and freight overhead are present, the massive top-line growth generated by US offline store adoption and multi-nation European monetization effortlessly scales past these cost burdens. Moving forward, the second-half expansion of the new device pipeline and the exact regulatory approval timelines for the medical segment (EBD) will serve as pivotal inflection points for additional valuation re-rating.
📢 Disclaimer & Source Information
- Source: This content has been newly structured and written based on publicly disclosed financial facts and numerical data from brokerage research reports.
- Investment Risk Warning: This material is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest entirely with the individual investor.
- Contact: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
